par Paridaens, R. ;Dirix, Luc Y;Beex, Louk;Nooij, Marianne;Cufer, T;Lohrisch, C;Biganzoli, Laura ;Van Hoorebeeck, Irène;Duchateau, L;Lobelle, Jean Pierre;Piccart-Gebhart, Martine
Référence Clinical breast cancer, 1 Suppl 1, page (S19-S21)
Publication Publié, 2000-09
Référence Clinical breast cancer, 1 Suppl 1, page (S19-S21)
Publication Publié, 2000-09
Article révisé par les pairs
Titre: |
|
Auteur: | Paridaens, R.; Dirix, Luc Y; Beex, Louk; Nooij, Marianne; Cufer, T; Lohrisch, C; Biganzoli, Laura; Van Hoorebeeck, Irène; Duchateau, L; Lobelle, Jean Pierre; Piccart-Gebhart, Martine |
Informations sur la publication: | Clinical breast cancer, 1 Suppl 1, page (S19-S21) |
Statut de publication: | Publié, 2000-09 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Administration, Oral |
Androstadienes -- adverse effects | |
Androstadienes -- therapeutic use | |
Antineoplastic Agents, Hormonal -- therapeutic use | |
Aromatase Inhibitors -- adverse effects | |
Aromatase Inhibitors -- therapeutic use | |
Breast Neoplasms -- drug therapy | |
Breast Neoplasms -- pathology | |
Disease Progression | |
Female | |
Humans | |
Neoplasm Metastasis | |
Tamoxifen -- therapeutic use | |
Treatment Outcome | |
Note générale: | Clinical Trial |
Clinical Trial, Phase II | |
Journal Article | |
Multicenter Study | |
Randomized Controlled Trial | |
Research Support, Non-U.S. Gov't | |
Langue: | Anglais |
Identificateurs: | urn:issn:1526-8209 |
info:pmid/11970745 |